Arrowhead Pharmaceuticals Inc (ARWR) reported better-than-expected financial results for the fourth quarter of fiscal 2025. The company's earnings per share (EPS) came in at $-0.18, surpassing Wall Street's consensus estimate of $-0.25 by $0.07. Revenue for the quarter reached $0.3 billion, exceeding expectations of $0.2 billion.
This update provides insight into Arrowhead's operational performance and financial health, reflecting stronger-than-anticipated business fundamentals. The company engages in the development of medicines targeting intractable diseases through gene silencing, utilizing its proprietary Targeted RNAi Molecule (TRiMTM) platform.
Arrowhead Pharmaceuticals, headquartered in Pasadena, California, currently has around 16 clinical-stage investigational medicines. Its diverse pipeline spans various therapeutic areas, including cardiometabolic, pulmonary, liver, muscle, and central nervous system disorders.
The company plans to host an earnings conference call to discuss these results and provide additional commentary on its performance. Investors are encouraged to review the full earnings release and management's insights for a comprehensive understanding of the quarter's results and future outlook.
Upcoming earnings reports include estimates of $-1.36 EPS and $32.8 million in revenue for August 5, 2026, and $-0.79 EPS with $100.5 million in revenue for May 11, 2026.